|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Centocor, Inc. - SWOT Analysis
|
| Published Date:
October 2008
Published By:
Datamonitor
Page Count:
16
Order Code:
R313-41411
|
|
|
|
Datamonitor's Centocor, Inc. SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Centocor, a wholly-owned subsidiary of Johnson & Johnson (J&J), is a biopharmaceutical company engaged in the research, development and manufacturing of drugs for the treatment of immune disorders. The company markets blockbuster drug, Remicade (infliximab) in the US for a number of indications including rheumatoid arthritis and adult Crohn's disease. It primarily operates in the US. It is headquartered in Horsham, Pennsylvania.
Scope of the Report- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
|
Similar Products
• SensiGen, LLC. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• GUIDED THERAPEUTICS, INC. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Kuros Biosurgery AG Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• A&G Pharmaceutical, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Sequella, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Interface Biologics, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• China Sky One Medical, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Innocoll Technologies Ltd Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Endovasc, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
• Chembio Diagnostic Systems, Inc. Product Pipeline Analysis
Published Jan 2009 by Global Markets Direct
|
|
|
|
0 items
